cobas® Cdiff

Use left and right arrow keys to scroll between the tabs
Fast, accurate results to inform patient care
C. difficile infection (CDI) is the most common healthcare-associated infection worldwide, affecting approximately 500,000 Americans each year1 and resulting in an estimated $5.4 billion in additional healthcare costs in the U.S.2 The cobas® Cdiff assay provides accurate, on-demand results in just 20 minutes for the detection of toxigenic C. difficile, empowering informed isolation decisions and better management of patients with a suspected C. diff infection. With just three simple steps, the cobas® Cdiff assay can streamline the diagnosis of CDI while providing lab-quality results, empowering informed isolation decisions and better patient management.
cobas® Cdiff specifications
View Full Tablecobas® Cdiff specifications
Instrument |
cobas® liat system |
Targets |
C. difficile Toxin B (tcdB) |
Registration | FDA 510(k) cleared, Moderately Complex |
Time to result |
~20 minutes |
Sample type |
Unformed stool sample in cobas® PCR media |
Reagents |
Ready-to-use, pre-packed tube format |
Kit Storage |
2–8°C |
Collection media |
cobas® PCR Uni Swab Sample Kit |
Technology |
Real-time PCR |
Sample extraction |
Fully automated and integrated |
Control |
Internal sample processing control, positive and negative controls |
cobas® Cdiff ordering information
View Full Tablecobas® Cdiff ordering information
Material Number | Alternative Catalog Number |
Material Description |
Pack Size |
Pack size Description |
07454945190 | KIT COBAS CDIFF | 1 pack | 20 tests | |
07454970190 | KIT COBAS CDIFF QC | 1 pack | 5 sets | |
07958030190 | cobas PCR Media Uni Swab Sample Kit | 1 pack | 100 uni swab sample packets |
Would you like to know more about the cobas® Cdiff assay?
Please submit your information in the following form to be contacted by a Roche representative with more details about the cobas® Cdiff assay.
References
- Guh AY, Mu Y, Winston LG et al. N Engl J Med 2020;382:1320–30. DOI: 10.1056/NEJMoa1910215.
- Desai K, Gupta SB, Dubberke ER et al. Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach. BMC Infect Dis2016; 16:303–12.
- cobas® Cdiff IVD Instructions for Use